Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$90,000.00

Rapid diagnostic chips for detection and determination of the severity of urinary tract infection

EF 2018-19

Résumé
Children presenting a fever without known sources need to be checked for bacterial urinary tract infection (UTI), which may involve infection in the kidneys, or acute pyelonephritis (APN), that can result in permanent kidney damage. Current tests involve costly and lengthy urine culturing for UTI which requires several days and is prone to contamination for young children that are not toilet-trained, and renal imaging with a radioactive tracer which is costly, complicated, and exposes children to carcinogenic radiation.*This proposal builds on an existing collaborative effort between the applicant's lab at McGill University with Sensoreal and Parallex BioAssays to develop diagnostic microfluidic chips that directly detect multiple bacterial pathogens in urine and measure blood protein biomarkers for APN. This microchip-based, rapid, sensitive, low-cost and minimally invasive diagnostic device would allow routine testing for UTI and APN, determination of the severity, thus providing high quality diagnosis to guide clinical decision and treatments without the need for neither expensive and lengthy urine culturing nor invasive radioisotope-based renal scanning. This innovative clinical diagnostic technology will impact the Canadian healthcare and accelerate Sensoreal and Parallex BioAssays's product development.*
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
506998-2016
Name nom
Juncker, David
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2016
Award amount
90000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
2
Nb partie
2
Application title
Rapid diagnostic chips for detection and determination of the severity of urinary tract infection
Keyword
NSERC
Application summary
Children presenting a fever without known sources need to be checked for bacterial urinary tract infection (UTI), which may involve infection in the kidneys, or acute pyelonephritis (APN), that can result in permanent kidney damage. Current tests involve costly and lengthy urine culturing for UTI which requires several days and is prone to contamination for young children that are not toilet-trained, and renal imaging with a radioactive tracer which is costly, complicated, and exposes children to carcinogenic radiation.*This proposal builds on an existing collaborative effort between the applicant's lab at McGill University with Sensoreal and Parallex BioAssays to develop diagnostic microfluidic chips that directly detect multiple bacterial pathogens in urine and measure blood protein biomarkers for APN. This microchip-based, rapid, sensitive, low-cost and minimally invasive diagnostic device would allow routine testing for UTI and APN, determination of the severity, thus providing high quality diagnosis to guide clinical decision and treatments without the need for neither expensive and lengthy urine culturing nor invasive radioisotope-based renal scanning. This innovative clinical diagnostic technology will impact the Canadian healthcare and accelerate Sensoreal and Parallex BioAssays's product development.*